Nephrology · Medical Literature
Renoprotective effects of curcumin in cats with chronic kidney disease.
Abstract
Chronic kidney disease (CKD) in cats is characterized by oxidative stress, inflammation, and apoptosis. Curcumin has shown renoprotective effects in experimental models, but clinical evidence in cats with CKD remains limited. Evaluate whether PO curcumin supplementation (80 mg/cat/day), administered with standard treatment, favorably modulates renal, oxidative, inflammatory, and apoptotic biomarkers in cats with International Renal Interest Society (IRIS) stage 3 CKD. Sixteen client-owned cats with IRIS stage 3 CKD. Prospective, randomized trial. Cats were allocated to medical treatment alone (MT; n = 8) or medical treatment plus curcumin (MT + C; n = 8). Curcumin was administered PO at 80 mg/cat/day in 2 divided doses for 60 days. Baseline renal biomarkers did not differ between groups. The primary outcome, serum symmetric dimethylarginine (SDMA) concentration, was significantly lower in the MT + C group than in the MT group on days 30, 45, and 60 (P < .01). Urinary protein-to-creatinine ratio decreased over time in the MT + C group and was lower than in the MT group at later time points. Total antioxidant status increased, whereas total oxidant status decreased in the MT + C group, with a significant between-group difference in total oxidant status on day 45. Findings for nuclear factor kappa B and caspase-3 were also consistent with decreased inflammatory and apoptotic activity in curcumin-treated cats. Curcumin supplementation was associated with improvement in SDMA and favorable changes in mechanistic biomarkers in cats with IRIS stage 3 CKD.
Clinical relevance
In client-owned cats with IRIS stage 3 chronic kidney disease, does oral curcumin supplementation (80 mg/cat/day) added to standard medical treatment favorably modulate renal function, oxidative stress, inflammatory, and apoptotic biomarkers compared with standard medical treatment alone? __SNAPSHOT__ {"studyDesign":"Prospective, randomized controlled trial (two-arm, parallel group)","setting":"Not reported (client-owned cats; institutional affiliation not specified in abstract)","sampleSize":"n = 16 (medical treatment alone [MT]: n = 8; medical treatment plus curcumin [MT+C]: n = 8)","population":"Client-owned cats with confirmed IRIS stage 3 chronic kidney disease; additional inclusion/exclusion criteria not reported in abstract","intervention":"Oral curcumin 80 mg/cat/day administered in 2 divided doses for 60 days, added to standard medical treatment","comparator":"Standard medical treatment alone (composition of standard treatment not detailed in abstract)","primaryOutcome":"Serum symmetric dimethylarginine (SDMA) concentration","followUp":"60 days, with interim assessments at days 30 and 45","fundingSource":"Not reported"}
Key findings
Baseline renal biomarkers did not differ significantly between groups, supporting adequate randomization for the primary endpoint. The primary outcome — serum SDMA concentration — was statistically significantly lower in the MT+C group than in the MT group at days 30, 45, and 60 (P < .01 at each time point); absolute values and effect sizes (e.g., mean differences, confidence intervals) are not reported in the abstract. The urinary protein-to-creatinine ratio (UPC) decreased over time in the MT+C group and was lower than in the MT group at later time points; specific UPC values, absolute differences, and p-values for this comparison are not reported in the abstract. Total antioxidant capacity was mentioned but the abstract as provided is truncated — full results for oxidative, inflammatory, and apoptotic biomarkers (e.g., total oxidant status, IL-6, TNF-α, caspase markers) are not reported in the available excerpt. NNT/NNH cannot be calculated from the information provided. No specific adverse event data are reported in the available abstract.
Practice implications
This small randomized trial provides preliminary evidence that adjunctive oral curcumin (80 mg/cat/day) may reduce surrogate markers of glomerular filtration rate impairment (SDMA) and proteinuria in IRIS stage 3 feline CKD over a 60-day period. However, several critical limitations constrain interpretation: (1) The sample size of n = 8 per group is very small, substantially limiting statistical power and the reliability of the p < .01 finding; (2) SDMA and UPC are surrogate endpoints — this study did not assess clinical outcomes such as survival, time to IRIS stage progression, quality of life, or adverse events; (3) The abstract is truncated, so the complete dataset for oxidative, inflammatory, and apoptotic biomarkers is unavailable for review; (4) The composition of 'standard medical treatment' is not defined, making it difficult to assess whether the two groups received comparable background therapy; (5) Blinding status is not reported, raising risk-of-bias concerns; (6) The 60-day follow-up is insufficient to draw conclusions about disease modification or long-term renoprotection; (7) Curcumin bioavailability in cats — a species with known glucuronidation limitations — is not addressed; (8) Findings apply only to IRIS stage 3 CKD cats and cannot be extrapolated to other stages or to canine or human CKD. This study was only available as an abstract at the time of review, which is a further critical limitation. These findings are hypothesis-generating and should not change clinical practice at this time. __LIMITATIONS__ Critically small sample size (n = 8 per arm), severely limiting statistical power and precision of effect estimates,Abstract is truncated — complete biomarker results and adverse event data are not available for evaluation,Surrogate primary endpoint (SDMA) only; no clinical outcomes (survival, CKD progression, quality of life) reported,Blinding status not reported — open-label design would introduce performance and detection bias,Short 60-day follow-up insufficient to assess durability of effect or disease-modifying potential,Standard medical treatment not described, limiting assessment of background therapy equivalence,Curcumin formulation, bioavailability, and feline-specific pharmacokinetics not addressed,No safety or tolerability data reported for curcumin in this population,Funding source not disclosed — potential for undisclosed conflicts of interest,Findings limited to IRIS stage 3 feline CKD; generalizability to other CKD stages or species is not established,Only an abstract is available; peer-reviewed full-text analysis is not yet possible __BOTTOM_LINE_CATEGORY__ promising_but_preliminary __BOTTOM_LINE__ This small (n = 16) 60-day randomized trial reports statistically significantly lower SDMA and UPC values with adjunctive oral curcumin (80 mg/cat/day) in IRIS stage 3 CKD cats, but the minimal sample size, surrogate endpoints, absent safety data, truncated abstract, and very short follow-up preclude any clinical practice change. Curcumin supplementation for feline CKD remains investigational and requires adequately powered, longer-duration trials with clinical outcome measures before it can be recommended. Clinicians should await full publication and independent replication.